Agri Ibrahim Cecen University
Ağrı, 04100, Turkey (Türkiye)
NCT Number: NCT05056688
Aim: One of the cheapest, easiest and most effective ways to detect testicular cancer early is to resort to early detection screening methods associated with health beliefs about testicular cancer, and the second is to self-examine the testicles. In the country, there are a limited number of studies on the health beliefs and early diagnosis behaviors of young adult men for testicular cancer. For this reason, the study was conducted to determine the effect of online education given to young adults on testicular cancer health beliefs and behavior.
Material and method: The research was conducted as a randomized controlled experimental study. The study population consisted of 768 individuals who applied to Family Health Centers affiliated to Agri Provincial Health Directorate between April 2021 and June 2022, and the sample of the research consisted of 90 individuals selected from the population using the improbable random sampling method. "Descriptive Feature Form", "Champion's Health Belief Model Scale in Testicular Cancer Screenings" were used to collect data. In the analysis of data; percentile distribution, chi-square, Fisher-Freeman-Halton Exact test, t-test in independent groups, Repeated Measures ANOVA Test, Friedman Test, One Way ANOVA test, Kruskall Wallis test, and post hoc analyzes (Bonferroni, Games Howell, Dunn) were used.
Looking for future studies?
Notify Me18 year–35 year
Male
Interventional
Not applicable
Ağrı, 04100, Turkey (Türkiye)
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The investigators will use the Testicular Model BSE/TSE Trainer to transform individuals' routine testicular self-examination into behavior.
Time frame: Four monts
Individuals in the experimental and control group were evaluated with "Champion's Health Belief Model Scale in Testicular Cancer Screening". The effect of the training given to people in the online training group, which cannot be given to the control group, was changed at the end of 16 weeks with the mid-test "Champion's Health Belief Model Scale in Testicular Cancer Screening". A minimum of 26 points and a maximum of 130 points are obtained from Champion's Health Belief Model Scale in Testicular Cancer Screenings. The sub-dimensions of the scale are evaluated separately and there is no total score.
Time frame: Three monts
The mid-test for individuals in the experimental and control group was evaluated by the "Champion's Health Belief Model Scale in Testicular Cancer Screening". The effect of training given to those who could not be given to the control group in the online training group was replaced by the "Champion's Health Belief Model Scale in Testicular Cancer Screening" final test 3 months after training. A minimum of 26 points and a maximum of 130 points are obtained from Champion's Health Belief Model Scale in Testicular Cancer Screenings. The sub-dimensions of the scale are evaluated separately and there is no total score.
Agri Ibrahim Cecen University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03426865
Endocrine Gland Neoplasms, Endocrine System Diseases
Dallas, Texas, United States
View Trial DetailsNCT06309732
Endocrine Gland Neoplasms, Endocrine System Diseases
London, United Kingdom
View Trial DetailsNCT04122430
Endocrine Gland Neoplasms, Endocrine System Diseases
Parkville, Victoria, Australia
View Trial DetailsNCT02890030
Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions
Indianapolis, Indiana, United States
View Trial Details